FDA Clearance and U.S. Launch of Innovative Nonsurgical Procedure for Chronic Rhinitis

UltraSight Raises $13 million to Bring AI Guidance for Cardiac Ultrasound to Patient Point of Care

The Yozma Group Korea, Atain Specialty Insurance Company and the Weizmann Institute of Science participated in the round.

Jon Hopkins New Senior Vice President-Chief Development Officer of Legion Healthcare Partners

Over the past 23 years, Jon has held various positions at Varian Medical Systems including Director of Sales, Americas West & Latin America, Varian Proton Solutions and prior Director of Worldwide Sales, Varian Particle Therapy.

Sinan Batman Appointed CTO of TeraRecon

Batman brings rich industry experience to TeraRecon, including Chief Engineer at Carestream/Kodak Health Group, where he defined the vision for image-centric workflow information systems.

The RhinAer™ Stylus is an innovative device for nonsurgical treatment of chronic rhinitis.

Aerin Medical notes more than 30 million Americans suffer from nonallergic rhinitis.1 Patients with the condition suffer from a runny nose, post-nasal drip, congestion, chronic cough, and other symptoms. For many patients, management with medications and sprays is inadequate. The RhinAer procedure provides lasting relief by directly disrupting the signals that cause symptoms. The procedure can be performed under a local anesthetic in an ENT physician’s office, with no incisions and minimal discomfort.

“Chronic rhinitis can significantly affect quality of life and impact daily activities,” said Adil A. Fatakia, M.D., a rhinologist at West Jefferson Medical Center in Marrerro, La. “The RhinAer procedure’s compelling clinical results, including its high responder rate, clean side effect profile, and tolerability, make it a highly attractive option for my patients.”

Clinical results from the prospective, multi-center pivotal clinical trial of the RhinAer Stylus demonstrated meaningful benefits to patients. In the study, 96% of patients treated with the RhinAer procedure reported an improvement in their rhinitis symptoms at six months, with symptoms improving on average by 61%. The procedure was safe and generally well-tolerated. Notably, significant improvements were demonstrated for runny nose and post-nasal drip, the most bothersome chronic rhinitis symptoms.

“The FDA clearance and launch of our second nonsurgical innovation for ENT physicians and patients is a significant milestone for Aerin,” said Fred Dinger, President and CEO. “More than 13,000 patients with nasal airway obstruction have now been treated with our first product, the VivAer® Stylus with the Aerin™ Console. With the addition of the RhinAer Stylus we now offer ENT physicians a platform solution that can be used to improve the lives of the millions of patients suffering from chronic rhinitis.”

Both procedures rely on Aerin’s proprietary temperature-controlled technology, which has been developed and optimized for the nasal airway to provide a precise therapeutic effect while minimizing risk to surrounding tissue.


References

1 Scarupa MD, Kaliner MA. Nonallergic rhinitis, with a focus on vasomotor rhinitis: clinical importance, differential diagnosis, and effective treatment recommendations. World Allergy Organ J. 2009; 2(3):20-25. doi:10.1097/WOX.0b013e3181990aac.

spot_img

DON'T MISS

Subscribe to Medical Device News Magazine here.

Related Articles